Today: 21 May 2026
Fortescue (ASX:FMG) share price slips after iron ore cools — what traders watch next
8 January 2026
1 min read

Fortescue (ASX:FMG) share price slips after iron ore cools — what traders watch next

Sydney, Jan 8, 2026, 16:50 AEDT — After-hours

Fortescue Ltd (FMG.AX) shares slipped 0.2% on Thursday to close at A$22.75, paring a small slice off the iron ore miner’s recent strength.

The move matters because iron ore is doing most of the heavy lifting for Australian miners right now, and Fortescue is one of the market’s cleanest ways to express that view. When the ore price shifts, the stock usually shifts with it.

Iron ore futures — contracts linked to an expected future price — jumped to multi-month highs after China pledged to ease monetary policy, a Reuters report showed, putting the steelmaking raw material back in the middle of the trade.

Australia’s benchmark S&P/ASX 200 ended up 0.3%, but miners eased as iron ore prices slipped into the close, with the raw materials sector down 0.6%. “Commodities are slipping, setting a cautious tone for the local session,” Moomoo dealing manager Jimmy Tran said, as BHP, Rio Tinto and Fortescue moved lower while iron ore futures eased from multi-month highs. ABC

For Fortescue, the near-term question is whether the commodity rally holds long enough to show up in realised pricing and cash flow, or whether it proves another short burst that fades before the next batch of operating numbers lands. Investors will be watching any clues on volumes, costs and how quickly sentiment turns when the ore tape goes quiet.

Technically, the stock has traded between A$13.18 and A$23.38 over the past year, leaving it close to the top end of its range as traders weigh momentum against valuation.

But the downside case is simple. If iron ore gives back more of its recent gains, or if the Australian dollar strengthens sharply against the U.S. dollar and squeezes translated revenue, miners can reprice quickly.

Stock Market Today

  • Analysts Boost Broadcom Price Targets Despite Stock Dip
    May 20, 2026, 11:22 PM EDT. Broadcom (AVGO) shares fell 6.5% to $411.07 on May 19, retreating from a record high of $439.79 on May 14. Despite this drop, several major analysts raised their price targets. Wells Fargo lifted its target to $545 from $430, TD Cowen to $500 from $405, and UBS to $490 from $475, all maintaining buy ratings. Evercore ISI's Mark Lipacis, a top-ranked analyst, raised his target to $582, citing growing demand for Broadcom's custom AI chips amid shifts in AI workloads. Risks remain from semiconductor market volatility and geopolitical tensions impacting chip deals. Broadcom's strategic moves, including its VMware acquisition and partnerships with Google and Meta for AI-focused chips, position it well in enterprise infrastructure and AI growth.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Wall Street jolted by Trump buyback, home-buying moves; S&P 500 slips, Nasdaq steadied by AI
Previous Story

Wall Street jolted by Trump buyback, home-buying moves; S&P 500 slips, Nasdaq steadied by AI

CapitaLand Investment stock climbs after S$260 million Singapore automated logistics bet
Next Story

CapitaLand Investment stock climbs after S$260 million Singapore automated logistics bet

Go toTop